Genetic background influences therapeutic effectiveness of VEGF

Biochemical and Biophysical Research Communications

Volumn 310, Issue 1, 2003, Pages 143-147

  Fukino, Keiko ^a   Sata, Masataka ^a,b   Seko, Yoshinori ^a   Hirata, Yasunobu ^a   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Angiogenesis; Collateral; Mouse; Receptor; Strain; VEGF

Indexed keywords

RECOMBINANT VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; COLLATERAL CIRCULATION; CONTROLLED STUDY; DISEASE SIMULATION; EXPERIMENTAL MODEL; GENE TRANSFER; GENETIC ASSOCIATION; GENETIC TRAIT; HEMOPERFUSION; MALE; MORPHOLOGICAL TRAIT; MOUSE; MOUSE STRAIN; MUSCLE ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECIES COMPARISON; STRAIN DIFFERENCE;

EID: 0141849093     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.08.134     Document Type: Article

References (24)

1. Folkman J. Clinical-applications of research on angiogenesis. N. Engl. J. Med. 333:1995;1757-1763.
2. Freedman S., Isner J.M. Therapeutic angiogenesis for ischemic cardiovascular disease. J. Mol. Cell. Cardiol. 33:2001;379-393.
3. Schultz A., Lavie L., Hochberg I., Beyar R., Stone T., Skorecki K., Lavie P., Roguin A., Levy A.P. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation. 100:1999;547-552.
4. 165 following intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 97:1998;1114-1123.
5. Rosengart T.K., Lee L.Y., Patel S.R., Sanborn T.A., Parikh M., Bergman G.W., Hachamovitch R., Szulc M., Kligfield P.D., Okin P.M., Hahn R.T., Devereux R.B., Post M.R., Hackett N.R., Foster T., Grasso T.M., Lesser M.L., Isom O.W., Crystal R.G. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 100:1999;468-474.
6. Lee R.J., Springer M.L., Blanco-Bose W.E., Shaw R., Ursell P.C., Blau H.M. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation. 102:2000;898-901.
7. Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med. 6:2000;1102-1103.
8. Thurston G., Suri C., Smith K., McClain J., Sato T.N., Yancopoulos G.D., McDonald D.M. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 286:1999;2511-2514.
9. Couffinhal T., Silver M., Zheng L.P., Kearney M., Witzenbichler B., Isner J.M. Mouse model of angiogenesis. Am. J. Pathol. 152:1998;1667-1679.
10. Rivard A., Silver M., Chen D., Kearney M., Magner M., Annex B., Peters K., Isner J.M. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am. J. Pathol. 154:1999;355-363.
11. Rivard A., Fabre J.E., Silver M., Chen D., Murohara T., Kearney M., Magner M., Asahara T., Isner J.M. Age-dependent impairment of angiogenesis. Circulation. 99:1999;111-120.
12. Faraci F.M., Sigmund C.D. Vascular biology in genetically altered mice. Smaller vessels, bigger insight. Circ. Res. 85:1999;1214-1225.
13. Marshall E. The rise of the mouse, biomedicine's model animal. Science. 288:2000;248-257.
14. Gregory S.G., Sekhon M., Schein J., Zhao S., Osoegawa K., Scott C.E., Evans R.S., Burridge P.W., Cox T.V., Fox C.A., Hutton R.D., Mullenger I.R., Phillips K.J., Smith J., Stalker J., Threadgold G.J., Birney E., Wylie K., Chinwalla A., Wallis J., Hillier L., Carter J., Gaige T., Jaeger S., Kremitzki C., Layman D., Maas J., McGrane R., Mead K., Walker R., Jones S., Smith M., Asano J., Bosdet I., Chan S., Chittaranjan S., Chiu R., Fjell C., Fuhrmann D., Girn N., Gray C., Guin R., Hsiao L., Krzywinski M., Kutsche R., Lee S.S., Mathewson C., McLeavy C., Messervier S., Ness S., Pandoh P., Prabhu A.L., Saeedi P., Smailus D., Spence L., Stott J., Taylor S., Terpstra W., Tsai M., Vardy J., Wye N., Yang G., Shatsman S., Ayodeji B., Geer K., Tsegaye G., Shvartsbeyn A., Gebregeorgis E., Krol M., Russell D., Overton L., Malek J.A., Holmes M., Heaney M., Shetty J., Feldblyum T., Nierman W.C., Catanese J.J., Hubbard T., Waterston R.H., Rogers J., de Jong P.J., Fraser C.M., Marra M., McPherson J.D., Bentley D.R. A physical map of the mouse genome. Nature. 418:2002;743-750.
15. Sata M., Nishimatsu H., Suzuki E., Sugiura S., Yoshizumi M., Ouchi Y., Hirata Y., Nagai R. Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia. FASEB J. 15:2001;2530-2532.
16. Marti H.H., Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc. Natl. Acad. Sci. USA. 95:1998;15809-15814.
17. Sata M., Walsh K. Endothelial cell apoptosis induced by oxidized LDL is associated with the downregulation of the cellular caspase inhibitor FLIP. J. Biol. Chem. 273:1998;33103-33106.
18. Aihara H., Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 16:1998;867-870.
19. Couffinhal T., Silver M., Kearney M., Sullivan A., Witzenbichler B., Magner M., Annex B., Peters K., Isner J.M. Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE-/- mice. Circulation. 99:1999;3188-3198.
20. 165 in patient with ischaemic limb. The Lancet. 348:1996;370-374.
21. Freeman M.R., Schneck F.X., Gagnon M.L., Corless C., Soker S., Niknejad K., Peoples G.E., Klagsbrun M. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res. 55:1995;4140-4145.
22. Inoue M., Itoh H., Ueda M., Naruko T., Kojima A., Komatsu R., Doi K., Ogawa Y., Tamura N., Takaya K., Igaki T., Yamashita J., Chun T.H., Masatsugu K., Becker A.E., Nakao K. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation. 98:1998;2108-2116.
23. Guo P., Fang Q., Tao H.Q., Schafer C.A., Fenton B.M., Ding I., Hu B., Cheng S.Y. Overexpression of vascular endothelial growth factor by MCF-7 breast cancer cells promotes estrogen-independent tumor growth in vivo. Cancer Res. 63:2003;4684-4691.
24. Spyridopoulos I., Brogi E., Kearney M., Sullivan A.B., Cetrulo C., Isner J.M., Losordo D.W. Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-A: balance between growth and death signals. J. Mol. Cell. Cardiol. 29:1997;1321-1330.